Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: A retrospective analysis

Jeffrey L. Cummings, Steven H. Ferris, Martin Farlow, Jason T. Olin, Xiangyi Meng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to measure change. This was a hypothesis-forming study, designed to provide a basis for possible future research. Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients. Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain with rivastigmine 17.4 mg/24 h patch (p < 0.01), 9.5 mg/24 h patch (p = 0.02) and capsules (p < 0.01); similarly on the ADCS-CGIC ADL domain. The cognition portion of the CGIC correlated with the Alzheimer's Disease Assessment Scale cognitive subscale and the ADL section with the ADCS-ADL trial measures. Variance ascribable to these tools was small, indicating that CGIC detects changes not measured by the domain-specific tools. Conclusions: The results of this post hoc analysis suggest that the ADCS-CGIC accurately reflects changes in cognitive and functional domains measured by other tools; it captures changes not assessed by domain-specific instruments. Cognitive alterations show greatest correlation with total CGIC. These results may assist in analyzing and interpreting CGIC results in other trials.

Original languageEnglish
Pages (from-to)406-412
Number of pages7
JournalDementia and Geriatric Cognitive Disorders
Volume29
Issue number5
DOIs
StatePublished - Jun 2010

Fingerprint

Rivastigmine
Transdermal Patch
Capsules
Alzheimer Disease
Activities of Daily Living
Cognition
Placebo Effect
Aptitude
Randomized Controlled Trials
Placebos
Clinical Studies

Keywords

  • Activities of daily living
  • Alzheimer's disease
  • Behavior
  • Cognition
  • Rivastigmine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Cognitive Neuroscience

Cite this

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease : A retrospective analysis. / Cummings, Jeffrey L.; Ferris, Steven H.; Farlow, Martin; Olin, Jason T.; Meng, Xiangyi.

In: Dementia and Geriatric Cognitive Disorders, Vol. 29, No. 5, 06.2010, p. 406-412.

Research output: Contribution to journalArticle

@article{485473bea84142b89fdd2b1fb109b9f7,
title = "Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: A retrospective analysis",
abstract = "Background: The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to measure change. This was a hypothesis-forming study, designed to provide a basis for possible future research. Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients. Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain with rivastigmine 17.4 mg/24 h patch (p < 0.01), 9.5 mg/24 h patch (p = 0.02) and capsules (p < 0.01); similarly on the ADCS-CGIC ADL domain. The cognition portion of the CGIC correlated with the Alzheimer's Disease Assessment Scale cognitive subscale and the ADL section with the ADCS-ADL trial measures. Variance ascribable to these tools was small, indicating that CGIC detects changes not measured by the domain-specific tools. Conclusions: The results of this post hoc analysis suggest that the ADCS-CGIC accurately reflects changes in cognitive and functional domains measured by other tools; it captures changes not assessed by domain-specific instruments. Cognitive alterations show greatest correlation with total CGIC. These results may assist in analyzing and interpreting CGIC results in other trials.",
keywords = "Activities of daily living, Alzheimer's disease, Behavior, Cognition, Rivastigmine",
author = "Cummings, {Jeffrey L.} and Ferris, {Steven H.} and Martin Farlow and Olin, {Jason T.} and Xiangyi Meng",
year = "2010",
month = "6",
doi = "10.1159/000296073",
language = "English",
volume = "29",
pages = "406--412",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease

T2 - A retrospective analysis

AU - Cummings, Jeffrey L.

AU - Ferris, Steven H.

AU - Farlow, Martin

AU - Olin, Jason T.

AU - Meng, Xiangyi

PY - 2010/6

Y1 - 2010/6

N2 - Background: The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to measure change. This was a hypothesis-forming study, designed to provide a basis for possible future research. Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients. Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain with rivastigmine 17.4 mg/24 h patch (p < 0.01), 9.5 mg/24 h patch (p = 0.02) and capsules (p < 0.01); similarly on the ADCS-CGIC ADL domain. The cognition portion of the CGIC correlated with the Alzheimer's Disease Assessment Scale cognitive subscale and the ADL section with the ADCS-ADL trial measures. Variance ascribable to these tools was small, indicating that CGIC detects changes not measured by the domain-specific tools. Conclusions: The results of this post hoc analysis suggest that the ADCS-CGIC accurately reflects changes in cognitive and functional domains measured by other tools; it captures changes not assessed by domain-specific instruments. Cognitive alterations show greatest correlation with total CGIC. These results may assist in analyzing and interpreting CGIC results in other trials.

AB - Background: The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to measure change. This was a hypothesis-forming study, designed to provide a basis for possible future research. Methods: This retrospective analysis used data from a 24-week, randomized, placebo-controlled trial [study ENA713D2320 (IDEAL)] that evaluated rivastigmine patches and capsules in AD patients. Results: At week 24, significant treatment effects versus placebo were seen on the ADCS-CGIC cognitive domain with rivastigmine 17.4 mg/24 h patch (p < 0.01), 9.5 mg/24 h patch (p = 0.02) and capsules (p < 0.01); similarly on the ADCS-CGIC ADL domain. The cognition portion of the CGIC correlated with the Alzheimer's Disease Assessment Scale cognitive subscale and the ADL section with the ADCS-ADL trial measures. Variance ascribable to these tools was small, indicating that CGIC detects changes not measured by the domain-specific tools. Conclusions: The results of this post hoc analysis suggest that the ADCS-CGIC accurately reflects changes in cognitive and functional domains measured by other tools; it captures changes not assessed by domain-specific instruments. Cognitive alterations show greatest correlation with total CGIC. These results may assist in analyzing and interpreting CGIC results in other trials.

KW - Activities of daily living

KW - Alzheimer's disease

KW - Behavior

KW - Cognition

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=77952509769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952509769&partnerID=8YFLogxK

U2 - 10.1159/000296073

DO - 10.1159/000296073

M3 - Article

C2 - 20502014

AN - SCOPUS:77952509769

VL - 29

SP - 406

EP - 412

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 5

ER -